{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:22:12Z","timestamp":1791235332290,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.thromres.2025.109361","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T23:02:54Z","timestamp":1748473374000},"page":"109361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Control of warfarin treatment in patients with antiphospholipid syndrome and falsely high INR at point-of-care-testing"],"prefix":"10.1016","volume":"252","author":[{"given":"J\u00f8rn Dalsgaard","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Steffen","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Storgaard","family":"N\u00f8rskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.thromres.2025.109361_bb0005","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.thromres.2025.109361_bb0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2025.109361_bb0015","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR \/ EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.thromres.2025.109361_bb0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J. Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.thromres.2025.109361_bb0025","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1177\/1060028014546361","article-title":"Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant","volume":"48","author":"Crowl","year":"2014","journal-title":"Ann. Pharmacother."},{"issue":"7","key":"10.1016\/j.thromres.2025.109361_bb0030","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1592\/phco.24.9.838.36102","article-title":"Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant","volume":"24","author":"Rosborough","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.thromres.2025.109361_bb0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1055\/s-0037-1613743","article-title":"Monitoring oral anticoagulant therapy--INR values for the Owren prothrombin time","volume":"91","author":"Jackson","year":"2004","journal-title":"Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2025.109361_bb0040","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1515\/cclm-2017-0976","article-title":"International normalized ratio (INR) testing in Europe: between-laboratory comparability of test results obtained by quick and Owren reagents","volume":"56","author":"Meijer","year":"2018","journal-title":"Clin Chem Lab Med CCLM."},{"issue":"3","key":"10.1016\/j.thromres.2025.109361_bb0045","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1365-2141.2001.03178.x","article-title":"Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins","volume":"115","author":"Tripodi","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2025.109361_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102470","article-title":"Interference of lupus anticoagulant causing antiprothrombin and anti\u2013beta-2-glycoprotein I antibodies on international normalized ratio measurements: comparative analysis of international normalized ratio methods","volume":"8","author":"Gehlen","year":"2024","journal-title":"Res Pract Thromb Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2025.109361_bb0055","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/j.thromres.2012.01.011","article-title":"Antiphospholipid syndrome patients: the performance of Coagucheck XS in the monitoring of vitamin K-antagonists","volume":"129","author":"Barcellona","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2025.109361_bb0060","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.thromres.2022.01.021","article-title":"Warfarin monitoring and interference by lupus anticoagulant in patients with antiphospholipid syndrome","volume":"211","author":"Jepsen","year":"2022","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.thromres.2025.109361_bb0065","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2141.2005.05739.x","article-title":"An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation","volume":"131","author":"Fitzmaurice","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2025.109361_bb0070","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.13070","article-title":"Patient self-testing and self-management of oral anticoagulation with vitamin K antagonists: guidance from the British Committee for Standards in Haematology","volume":"167","author":"Jennings","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.thromres.2025.109361_bb0075","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/jth.14846","article-title":"Lupus anticoagulant detection in anticoagulated patients. Guidance from the scientific and standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the international society on thrombosis and Haemostasis","volume":"18","author":"Tripodi","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2025.109361_bb0080","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/jth.15217","article-title":"Monitoring of anticoagulation in thrombotic antiphospholipid syndrome","volume":"19","author":"Cohen","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2025.109361_bb0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct Oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes","volume":"81","author":"Khairani","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109361_bb0090","doi-asserted-by":"crossref","first-page":"SI24","DOI":"10.1093\/rheumatology\/kead571","article-title":"Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations","volume":"63","author":"Gaspar","year":"2024","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.thromres.2025.109361_bb0095","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/jth.14935","article-title":"Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the scientific and standardization committee of the International Society on thrombosis and Haemostasis","volume":"18","author":"Zuily","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2025.109361_bb0100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jacc.2022.10.015","article-title":"Warfarin is the preferred therapy for patients with thrombotic APS","volume":"81","author":"Crowther","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9508","key":"10.1016\/j.thromres.2025.109361_bb0105","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0140-6736(06)68139-7","article-title":"Self-monitoring of oral anticoagulation: a systematic review and meta-analysis","volume":"367","author":"Heneghan","year":"2006","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.thromres.2025.109361_bb0110","doi-asserted-by":"crossref","first-page":"472","DOI":"10.7326\/0003-4819-154-7-201104050-00005","article-title":"Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes","volume":"154","author":"Bloomfield","year":"2011","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.thromres.2025.109361_bb0115","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1023\/A:1018778914477","article-title":"Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management","volume":"9","author":"Samsa","year":"2000","journal-title":"J. Thromb. Thrombolysis"},{"issue":"2","key":"10.1016\/j.thromres.2025.109361_bb0120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.thromres.2008.04.021","article-title":"Results of the performance verification of the CoaguChek XS system","volume":"123","author":"Plesch","year":"2008","journal-title":"Thromb. Res."},{"issue":"12","key":"10.1016\/j.thromres.2025.109361_bb0125","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/jclinpath-2012-201049","article-title":"Point of care INR testing devices: performance of the Roche CoaguChek XS and XS plus in the UK NEQAS BC external quality assessment programme for healthcare professionals: four years\u2019 experience","volume":"65","author":"Kitchen","year":"2012","journal-title":"J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.thromres.2025.109361_bb0130","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1538-7836.2011.04568.x","article-title":"Precision and accuracy of point-of-care testing coagulometers used for self-testing and self-management of oral anticoagulation therapy","volume":"10","author":"Christensen","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2025.109361_bb0135","first-page":"99","article-title":"Control of oral anticoagulation in patients with the antiphospholipid syndrome--influence of the lupus anticoagulant on International Normalized Ratio. Groupe M\u00e9thodologie en H\u00e9mostase du Groupe d\u2019Etudes sur l\u2019H\u00e9mostases et la Thrombose","volume":"80","author":"Robert","year":"1998","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2025.109361_bb0140","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00277-015-2374-3","article-title":"Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome","volume":"94","author":"Isert","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.thromres.2025.109361_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-209013","article-title":"Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher?","author":"Baquero-Salamanca","year":"2015","journal-title":"BMJ Case Rep."},{"issue":"12","key":"10.1016\/j.thromres.2025.109361_bb0150","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2025.109361_bb0155","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/09612033221086134","article-title":"CoaguChek\u00ae XS versus standard laboratory prothrombin time for anticoagulant monitoring in patients with antiphospholipid syndrome","volume":"31","author":"Fonseca","year":"2022","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.thromres.2025.109361_bb0160","first-page":"1196","article-title":"Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies","volume":"94","author":"Perry","year":"2005","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2025.109361_bb0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/POC.0000000000000149","article-title":"Accuracy of CoaguChek XS in patients with antiphospholipid syndrome","volume":"16","author":"Taylor","year":"2017","journal-title":"Point Care J -Patient Test Technol"},{"issue":"1","key":"10.1016\/j.thromres.2025.109361_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2022.100011","article-title":"Interference in point-of-care international normalized ratio monitoring in patients with lupus anticoagulant is correlated with anti\u2013\u03b22-glycoprotein I antibody titers","volume":"7","author":"Noordermeer","year":"2023","journal-title":"Res Pract Thromb Haemost."},{"key":"10.1016\/j.thromres.2025.109361_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2023.02.005","article-title":"Recurrent thrombotic events after disappearance of antiphospholipid autoantibodies: a long-term longitudinal study in patients with antiphospholipid syndrome","volume":"224","author":"Ballul","year":"2023","journal-title":"Thromb. Res."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825001112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825001112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:16:10Z","timestamp":1751415370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825001112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"alternative-id":["S0049384825001112"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109361","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Control of warfarin treatment in patients with antiphospholipid syndrome and falsely high INR at point-of-care-testing","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109361","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109361"}}